ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., unveiled at the American Society of Human Genetics (ASHG) ...
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics (“Ambry”) announces the launch of powerful cardiovascular genetic testing panels for inherited cardiomyopathies and arrhythmias. These feature an ...
Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary ...
LEXINGTON, KY, UNITED STATES, March 11, 2026 /EINPresswire.com/ — The Child Neurology Foundation (CNF) today announced Ambry Genetics, now a wholly owned subsidiary ...
Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Tempus AI announced today it is acquiring genetic testing ...
Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced that its CARE Program (Comprehensive, Assessment, Risk, and ...
Shares of Tempus AI TEM gained 18.4% after it announced an agreement, on Nov. 4, 2024, to acquire Ambry Genetics for $600 million. This acquisition will likely help Tempus revolutionize healthcare by ...
Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics first implemented RNA testing in 2016 as part of a research and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results